Skip to main content
. 2017 Apr 30;8(28):45399–45414. doi: 10.18632/oncotarget.17535

Figure 7. The relationship between the initial expression levels of plasma microRNAs and the progression-free survival (PFS) of ALK-positive patients receiving crizotinib (n = 31).

Figure 7

(A) PFS of ALK-positive patients who received crizotinib therapy. (B) PFS of ALK-positive patients, stratified according to the expression levels of miR-28-5p. (C) PFS of ALK-positive patients, stratified according to the expression levels of miR-362-5p. (D) PFS of ALK-positive patients, stratified according to the expression levels of miR-660-5p. All survival rates were estimated using the Kaplan-Meier method.